 |
|
Anthrax test, developed by army and CDC, receives FDA approval
August 31, 2005A method for identifying Bacillus anthracis, the causative agent of anthrax, has been cleared for diagnostic use by the U.S. Food and Drug Administration (FDA). The test, known as the Gamma Phage Assay, was modified by scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to improve its performance and reliability when used with clinical specimens. The original form of the Gamma Phage Assay was first developed by the Centers for Disease Control and Prevention (CDC) in the mid-1950s.
The modified gamma phage method is the first diagnostic test to gain FDA approval for human use within the Laboratory Response Network (LRN). This network, established by the CDC, is charged with maintaining an integrated system of state and local public health, federal, military, and international laboratories that can respond to bioterrorism, chemical terrorism and other public health emergencies.
According to USAMRIID senior scientist John W. Ezzell, the Gamma Phage Assay is a classical bacteriological method that has been used at USAMRIID and other laboratories for years as part of an extensive array of methods used to identify B. anthracis. The gamma phage is a virus capable of entering bacterial cells and causing cell destruction, or lysis-and it is specific to B. anthracis.
"Because of that specificity, the gamma phage gives a highly readable result," Ezzell explained. "Wherever the virus is added to the surface of a culture plate that has been inoculated with suspicious anthrax colony growth, you can see clear zones where the B. anthracis cells have been destroyed-whereas other bacterial cells grow unaffected."
Well before the anthrax attacks of 2001, scientists at USAMRIID and the CDC recognized the need for an FDA accepted method for identifying B. anthracis in clinical specimens. In 2002, FDA's Division of Clinical Laboratory Devices agreed to recognize tests for B. anthracis as eligible for classification with a 510(k) premarket notification process-the designation given to devices and other non-biologics.
USAMRIID, with support from CDC, prepared and submitted a 510(k) Premarket Notification using both USAMRIID and CDC data on use of the gamma phage method. With FDA recognition of the assay as substantially equivalent to the classical assay used prior to 1976, it will be available for use for testing in designated civilian and military clinical laboratories.
"This is a big first step in helping to provide the LRN labs with FDA cleared assays," said Judy Sheldon, a regulatory affairs microbiologist with the CDC's Bioterrorism Preparedness and Response Program. "The work done at USAMRIID and here at CDC provided a solid scientific basis for FDA to evaluate the assay performance. This work has set a high bar for other tests to meet."
USAMRIID scientists standardized and validated the test to make it more rugged, more reproducible across laboratories, and more resistant to user error. They developed a clearly defined method for production of gamma phage that proved to be highly stable, as reflected in the extended shelf life of the B. anthracis-specific virus. USAMRIID then provided sufficient gamma phage material to CDC for distribution within the LRN, so that each laboratory will have the same material to be used in the test. In addition, USAMRIID developed Standard Operating Procedures for the assay to ensure that each laboratory in the LRN will run the test the same way. This also increases confidence in the final result.
"This represents a very significant milestone for both of our organizations, in that all of the medical diagnostic products that we are developing must eventually follow a similar pathway for approval to allow clinical diagnosticians to use these tests to positively identify pathogens," said Colonel George W. Korch, Jr., commander of USAMRIID. "Successes such as these demonstrate that we can translate our research efforts into products for our health care providers and clinical laboratory professionals."
US Army Medical Research Institute of Infectious D
"Because of that specificity, the gamma phage gives a highly readable result," Ezzell explained. "Wherever the virus is added to the surface of a culture plate that has been inoculated with suspicious anthrax colony growth, you can see clear zones where the B. anthracis cells have been destroyed-whereas other bacterial cells grow unaffected."
Well before the anthrax attacks of 2001, scientists at USAMRIID and the CDC recognized the need for an FDA accepted method for identifying B. anthracis in clinical specimens. In 2002, FDA's Division of Clinical Laboratory Devices agreed to recognize tests for B. anthracis as eligible for classification with a 510(k) premarket notification process-the designation given to devices and other non-biologics.
USAMRIID, with support from CDC, prepared and submitted a 510(k) Premarket Notification using both USAMRIID and CDC data on use of the gamma phage method. With FDA recognition of the assay as substantially equivalent to the classical assay used prior to 1976, it will be available for use for testing in designated civilian and military clinical laboratories.
"This is a big first step in helping to provide the LRN labs with FDA cleared assays," said Judy Sheldon, a regulatory affairs microbiologist with the CDC's Bioterrorism Preparedness and Response Program. "The work done at USAMRIID and here at CDC provided a solid scientific basis for FDA to evaluate the assay performance. This work has set a high bar for other tests to meet."
USAMRIID scientists standardized and validated the test to make it more rugged, more reproducible across laboratories, and more resistant to user error. They developed a clearly defined method for production of gamma phage that proved to be highly stable, as reflected in the extended shelf life of the B. anthracis-specific virus. USAMRIID then provided sufficient gamma phage material to CDC for distribution within the LRN, so that each laboratory will have the same material to be used in the test. In addition, USAMRIID developed Standard Operating Procedures for the assay to ensure that each laboratory in the LRN will run the test the same way. This also increases confidence in the final result.
"This represents a very significant milestone for both of our organizations, in that all of the medical diagnostic products that we are developing must eventually follow a similar pathway for approval to allow clinical diagnosticians to use these tests to positively identify pathogens," said Colonel George W. Korch, Jr., commander of USAMRIID. "Successes such as these demonstrate that we can translate our research efforts into products for our health care providers and clinical laboratory professionals."
US Army Medical Research Institute of Infectious D
Anthrax Current Events and Anthrax News RSSScientists Present 'Moving' Theory Behind Bacterial Decision-Making
Biochemists at North Carolina State University have answered a fundamental question of how important bacterial proteins make life-and-death decisions that allow them to function, a finding that could provide a new target for drugs to disrupt bacterial decision-making processes and related diseases.
Scripps research scientists identify blood component that turns bacteria virulent
Scientists from the Scripps Research Institute have discovered the key chemical that signals Bacillus anthracis, the bacterium that causes anthrax, to become lethal. This finding opens up new avenues of exploration for the development of treatments for bacterial infections.
Nature study demonstrates that bacterial clotting depends on clustering
Bacteria can directly cause human blood and plasma to clot-a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
Green catalysts provide promise for cleaning toxins and pollutants
Tetra-Amido Macrocyclic Ligands (TAMLs) are environmentally friendly catalysts with a host of applications for reducing and cleaning up pollutants, and a prime example of "green chemistry." Carnegie Mellon University's Terry Collins, the catalyst's inventor, believes that the small-molecule catalysts have the potential to be even more effective than previously proven.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas.
Francisella tularensis: Stopping a biological weapon
Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium.
Effective health messages may yield vaccine compliance among ER workers
Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now.
Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances
Security and law enforcement officials may some day have a new ally - a universal detection system that can monitor the air for virtually all of the major threat agents that could be used by terrorists.
New strategies against bird flu
The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS).
More Anthrax Current Events and Anthrax News Articles
| Anthrax: State of Euphoria (Guitar tablature) by Craig Anderton | |
 | The Anthrax Letters: A Medical Detective Story by Leonard A. Cole At 2:00am on October 2, 2001, Robert Stevens entered a hospital emergency room. Feverish, nauseated, and barely conscious, no one knew what was making him sick. It was the doctors and public health officials who solved this medical mystery. Stevens was the first fatal victim of bioterrorism in America. The events of September 11th and the anthrax attacks that followed only three weeks later were... |
| Attack of the Killer B's (Authentic Guitar-Tab) by Anthrax This album-matching folio contains 12 killer cuts never before included on any of the band's previous efforts. Selections include: Milk (Ode to Billy) * Bring the Noise * Keep It in the Family (live) * Startin' Up a Posse * Protest and Survive * Chromatic Death * I'm the Man '91 and... | |
 | Anthrax: Bioterror as Fact and Fantasy by Philipp Sarasin The potential for creating and using biological weapons to wreak havoc is an urgent concern not just in America, but worldwide. In fact, many security experts believe that the next act of widespread terrorism will likely come from a weapon of biochemical means. In Anthrax: Bioterror as Fact and Fantasy, Philipp Sarasin explores the real threats of biological weapons--in contrast to the idea... |
 | Bioterror: Anthrax, Influenza, and the Future of Public Health Security by R. William Johnstone This book uses the 2001 anthrax attacks as its point of departure for an analysis of the past, present, and future of America's preparedness to deal with major challenges to public health, including bioterrorism and pandemic flu. The study identified the strength and weaknesses of the system while making recommendations for improvements. This allows the U.S. to be better prepared if faced with a... |
 | Bioterrorism Anthrax Guidebook: For Healthcare Workers, Public Officers (Allied Health, Nurses, Doctors, Public Health workers, EMS workers, other emergency, ... of the Anthrax Threat and How to Handle It by Daniel Farb Anthrax has already been used as an instrument of bioterror, is a significant danger now, and is usually fatal in its inhalational form. Bioterrorism Anthrax teaches you about the organism that causes anthrax, its transmission and prevention, its laboratory diagnosis, its clinical manifestations and diagnosis, its treatment, and the bioterror parameters of the disease. The book is geared to... |
 | Anthrax (Deadly Diseases and Epidemics) by Janet M. Decker Experts in the field of microbiology tell the great "detective stories" of how some of the world's best-known deadly disease-causing microbes were first isolated, identified, and studied. Readers learn how these deadly viruses and bacteria cause disease and what steps have been taken to eradicate them. Most commonly associated with animals such as livestock, the infectious disease anthrax... |
 | Anthrax: The Investigation of a Deadly Outbreak by Jeanne Guillemin In April of 1979 the city of Sverdlovsk in Russia's Ural Mountains was struck by a frightening anthrax epidemic. Official Soviet documents reported sixty-four human deaths resulting from the ingestion of tainted meat sold on the black market, but U.S. intelligence sources implied a different story, and the lack of documentation left unresolved questions. In her riveting investigation of the... |
 | The Killer Strain: Anthrax and a Government Exposed by Marilyn W. Thompson A lethal germ is unleashed in the U.S. mail. A chain of letters spreads terror from Florida to Washington, D.C., from New York to Connecticut, from the halls of Congress to the assembly lines of the U.S. Postal Service. Five people die, and ten thousand more line up for antibiotics to protect against exposure. The government, already outsmarted by the terrorist hijackers of 9/11, leaves its... |
 | Spores, Plagues and History: The Story of Anthrax by Chris Holmes Spores, Plagues and History is the tale of one of history's most deadly bacterium, which has been causing natural disease since the time of Moses and man-made illness since World War II. Beginning with a description of the U.S. anthrax bioterrorism attacks of 2001, the story goes back in time to the earlist hint of the disease, the 5th and 6th plagues of Moses. Several epidemics are then... |
| © 2008 BrightSurf.com |